Entyvio and Metastatic neoplasm - a phase IV clinical study of FDA data
Metastatic neoplasm is reported only by a few people who take Entyvio.
The phase IV clinical study analyzes which people take Entyvio and have Metastatic neoplasm. It is created by eHealthMe based on reports of 18,116 people who have side effects while taking Entyvio from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
18,116 people reported to have side effects when taking Entyvio.
Among them, 2 people (0.01%) have Metastatic neoplasm.
What is Entyvio?
Entyvio has active ingredients of vedolizumab. It is often used in crohn's disease. eHealthMe is studying from 15,592 Entyvio users for its effectiveness, alternative drugs and more.
What is Metastatic neoplasm?
Metastatic neoplasm (spreadable cancer tumour) is found to be associated with 886 drugs and 482 conditions by eHealthMe.
Number of Entyvio and Metastatic neoplasm reports submitted per year:
Gender of people who have Metastatic neoplasm when taking Entyvio *:
- female: 50 %
- male: 50 %
Age of people who have Metastatic neoplasm when taking Entyvio *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 100 %
Common drugs people take besides Entyvio *:
- Prilosec: 1 person, 50.00%
- Norco: 1 person, 50.00%
- Miralax: 1 person, 50.00%
- Flexeril: 1 person, 50.00%
- Celexa: 1 person, 50.00%
- Bentyl: 1 person, 50.00%
Common side effects people have besides Metastatic neoplasm *:
- Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 1 person, 50.00%
Common conditions people have *:
- Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 50.00%
* Approximation only. Some reports may have incomplete information.
Do you take Entyvio and have Metastatic neoplasm?Check whether Metastatic neoplasm is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Metastatic neoplasm and when was it recovered:
Expand to all the drugs that have ingredients of vedolizumab:
Alternative drugs to, pros and cons of Entyvio:
- Entyvio (15,592 reports)
Common Entyvio side effects:
Browse all side effects of Entyvio:a b c d e f g h i j k l m n o p q r s t u v w x y z
Metastatic neoplasm treatments and more:
- Metastatic neoplasm (6,270 reports)
COVID vaccines that are related to Metastatic neoplasm:
- Metastatic neoplasm in Moderna COVID Vaccine
- Metastatic neoplasm in Pfizer BioNTech Covid Vaccine
- Metastatic neoplasm in Johnson and Johnson Covid Vaccine
Common drugs associated with Metastatic neoplasm:
All the drugs that are associated with Metastatic neoplasm:
- Metastatic neoplasm (886 drugs)
Common conditions associated with Metastatic neoplasm:
All the conditions that are associated with Metastatic neoplasm:
- Metastatic neoplasm (482 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on vedolizumab (the active ingredients of Entyvio) and Entyvio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Subsys and Speech Impairment (Adult) - now
- Rashes and Limb Deformity - 2 seconds ago
- Lipofen and High Blood Cholesterol - 2 seconds ago
- Duloxetine Hydrochloride and Mercaptopurine drug interaction - 3 seconds ago
- Metoclopramide and Desvenlafaxine Succinate drug interaction - 6 seconds ago
- Losartan and Stalevo 100 drug interaction - 13 seconds ago
- Pyridoxine and Taltz drug interaction - 14 seconds ago
- Keppra and Blood Fibrinogen Decreased - 17 seconds ago
- Zestoretic and Ampyra drug interaction - 22 seconds ago
- Centrum Silver and Arthroscopy Abnormal - 23 seconds ago